Digestive Diseases

Pancreatic Cancer

Adjuvant Therapy in Pancreatic Cancer

Thomas A. · Dajani K. · Neoptolemos J.P. · Ghaneh P.

Author affiliations

Division of Surgery and Oncology, School of Cancer Studies, University of Liverpool, Liverpool, UK

Keywords: Pancreatic cancerAdjuvant chemotherapyMeta-analysis

Related Articles for ""
Dig Dis 2010;28:684–692
https://doi.org/10.1159/000320099

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Pancreatic Cancer

Published online: November 18, 2010
Issue release date: November 2010

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 4

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Abstract

Pancreatic cancer is one of the major causes of cancer death in Europe with a 5-year survival rate of less than 5%. Although surgery cannot guarantee a cure, the 5-year survival does improve to around 10% following resection and increases to 20–30% with adjuvant chemotherapy. The European Study Group for Pancreatic Cancer (ESPAC) 1 trial was the first adequately powered, randomized study to assess chemoradiotherapy (CRT), concurrent with 5-fluorouracil (5-FU) and chemotherapy [5-FU/folinic acid (FA)] in resected pancreatic cancer. There was a survival benefit for adjuvant chemotherapy, but not for adjuvant CRT. Adjuvant CRT also did not improve survival in the EORTC multicenter prospective randomized trial by Klinkenbijl et al. (1999). The phase 3 RTOG 9704 trial compared pre- and postchemoradiation gemcitabine to pre- and postchemoradiation 5-FU. Overall there was no difference in overall survival between the 2 arms. Adjuvant gemcitabine significantly improved disease-free survival and later overall survival compared to surgery alone in the CONKO-001 randomized trial. The ESPAC-3(v2) trial compared adjuvant gemcitabine versus 5-FU/FA. The final 2-year analysis demonstrated median survival from resection of patients treated with 5-FU/FA was 23.0 months (95% CI: 21.1, 25.0) and 23.6 months (95% CI: 21.4, 26.4) for patients treated with gemcitabine. Further randomized studies will assess the role of adjuvant combination chemotherapy (ESPAC-4). The key to the future of adjuvant therapy in pancreatic cancer will be the identification of novel and effective agents, and better biomarker technology underpinned by translational research which will inform the design of future trials.

© 2010 S. Karger AG, Basel



Related Articles:

References

  1. CancerStats. http://info.cancerresearchuk.org/cancerstats/.
  2. Cress RD, Yin DX, Clarke L, Bold R, Holly EA: Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006;17:403–409.
    External Resources
  3. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP: Current standards of surgery for pancreatic cancer. Br J Surg 2004;91:1410–1427.
    External Resources
  4. Sperti C, Pasquali C, et al: Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21:195–200.
    External Resources
  5. Fortner JG, Klimstra DS, Senie RT, Maclean BJ: Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996;223:147–153.
    External Resources
  6. Müller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U, Breisch-Girbig D, Ceyhan GO, Büchler MW: Is there still a role for total pancreatectomy? Ann Surg 2007;246:966–974, discussion 974–965.
    External Resources
  7. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas – a multicenter, prospective, randomized study. Ann Surg 1998;228:508–514.
    External Resources
  8. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355–366, discussion 366–358.
    External Resources
  9. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ: A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618–628, discussion 628–630.
    External Resources
  10. Haslam JB, Cavanaugh PJ, Stroup SL: Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 1973;32:1341–1345.
    External Resources
  11. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865–867.
    External Resources
  12. Fossati V, Cattaneo GM, et al: The role of intraoperative therapy by electron beam and combination of adjuvant chemotherapy and external radiotherapy in carcinoma of the pancreas. Tumori 1995;81:23–31.
    External Resources
  13. Zerbi A, Fossati V, et al: Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 1994;73:2930–2935.
    External Resources
  14. Hiraoka T, Uchino R, et al: Combination of intraoperative radiation with resection of cancer of the pancreas. Int J Pancreatol 1990;7:201–207.
    External Resources
  15. Coquard R, Ayzac L, et al: Intraoperative radiotherapy in resected pancreatic cancer: feasibility and results. Radiother Oncol 1997;44:271–275.
    External Resources
  16. Reni M, Panucci MG, et al: Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2001;50:651–658.
    External Resources
  17. Sindelar W, Kinsella T: Randomised trial of intraoperative radiotherapy in resected carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1986;12(suppl 1):148.
  18. Sindelar W, Kinsella T: Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 1999;10(suppl 4):226–230.
    External Resources
  19. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.
    External Resources
  20. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776–782, discussion 782–774.
    External Resources
  21. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, van Cutsem E, van Dekken H, Klinkenbijl JH, Jeekel J: Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007;246:734–740.
    External Resources
  22. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621–633, discussion 633–636.
    External Resources
  23. Neoptolemos J, Stocken DD, Freiss H, Bassi C, Dunn J, Hickey H, Beger H-G, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler M: A randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.
    External Resources
  24. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576–1585.
    External Resources
  25. Twombly R: Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J Natl Cancer Inst 2008;100:1670–1671.
    External Resources
  26. Corsini MM, Miller RC, et al: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol 2008;26:3511–3516.
    External Resources
  27. Artinyan A, Hellan M, et al: Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer. Cancer 2008;112:34–42.
    External Resources
  28. Greco JA, Castaldo ET, et al: Survival benefit with adjuvant radiation in surgically resected pancreatic cancer (abstract 109). ASCO Gastrointestinal Cancers Symposium Proceedings, Chicago, 2007.
  29. Regine WF, Winter KW, et al: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs, gemcitabine (G) for resected pancreatic adenocarcinoma. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006;23(18S):4007.
  30. Burris HA 3rd, Moore MJ, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.
    External Resources
  31. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073–1081.
    External Resources
  32. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater – results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993;29A:698–703.
    External Resources
  33. Takada T, Amano H, et al: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685–1695.
    External Resources
  34. Kosuge T, Kiuchi T, et al: A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006;36:159–165.
    External Resources
  35. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267–277.
    External Resources
  36. Riess H, Neuhaus P, Post S, Gellert K, Ridwelski K, Schramm H, Zuelke C, Fahlke J, Langrehr J, Oettle H: CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC); in 33rd European-Society-for-Medical-Oncology Congress; 2008 Sep 12–16. Stockholm, Oxford Univ Press, 2008, pp 45–46.
  37. Neoptolemos JP, Stocken DD, Smith CT, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Buchler MW, European Study Grp Pancreatic C: Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials. Br J Cancer 2009;100:246–250.
    External Resources
  38. Ueno H, Kosuge T, et al: A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009;101:908–915.
    External Resources
  39. Richter J, Saif MW: Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the ‘2010 ASCO Gastrointestinal Cancers Symposium’. Orlando, FL, USA. January 22–24, 2010. JOP 2010;11:144–147.
    External Resources
  40. Bao PQ, Ramanathan RK, Moser AL, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Zeh H III: Phase II trial of adjuvant gemcitabine and erlotinib for resected pancreatic cancer. ASCO GI Cancers Symposium, Orlando, abstract 224.
  41. Yamamoto J, Saiura A, et al: Improved survival of left-sided pancreas cancer after surgery. Jpn J Clin Oncol 2010;40:530–536.
    External Resources
  42. Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005;92:1372–1381.
    External Resources
  43. Boeck S, Ankerst DP, Heinemann V: The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis. Oncology 2007;72:314–321.
    External Resources
  44. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JHG, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Buchler MW, Neoptolemos JP; Pancreatic Cancer Meta-Analysis Group: Influence of resection margins and treatment on survival in patients with pancreatic cancer – meta-analysis of randomized controlled trials. Arch Surg 2008;143:75–83.
    External Resources
  45. Farrell JJ, Elsaleh H, Garcia M, et al: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187–195.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Pancreatic Cancer

Published online: November 18, 2010
Issue release date: November 2010

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 4

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2010, Vol.28, No. 4-5

November 2010

Article

Recommend This
TOP